ArticleNeural regeneration research2021
The secretome of endothelial progenitor cells: a potential therapeutic strategy for ischemic stroke.
Article in Neural regeneration research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Efficacy and safety of very early rehabilitation for acute ischemic stroke: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Tuning Secretomes for Regenerative Medicine.Biology · 2026Review
- Hyperglycaemia perturbs blood-brain barrier integrity through its effects on endothelial cell characteristics and function.Tissue barriers · 2025Article
- Secretome from hypoxic mesenchymal stem cells as a potential therapy for ischemic stroke: Investigations onNarra J · 2024Article
- Anti-inflammatory Prowess of endothelial progenitor cells in the realm of biology and medicine.NPJ Regenerative medicine · 2024Review
- Comparative transcriptomic analysis of circulating endothelial cells in sickle cell stroke.Annals of hematology · 2024Article
- Review
- Analysis of endothelial progenitor cell subtypes as clinical biomarkers for elderly patients with ischaemic stroke.Scientific reports · 2023Article
- Construction of a novel cell-free tracheal scaffold promoting vascularization for repairing tracheal defects.Materials today. Bio · 2023Article
- Secretome of bovine umbilical vein endothelial cells promote wound healing regeneration on the second degree rat model burn injury.Open veterinary journal · 2023Article
- Therapeutic application of regeneration-associated cells: a novel source of regenerative medicine.Stem cell research & therapy · 2023Review
- MicroRNAs: protective regulators for neuron growth and development.Neural regeneration research · 2023Review
- Outgrowth Endothelial Cell Conditioned Medium Negates TNF-α-Evoked Cerebral Barrier Damage: A Reverse Translational Research to Explore Mechanisms.Stem cell reviews and reports · 2023Article
- CD34 positive cells as endothelial progenitor cells in biology and medicine.Frontiers in cell and developmental biology · 2023Review
- Article
- Protein kinase C-β distinctly regulates blood-brain barrier-forming capacity of Brain Microvascular endothelial cells and outgrowth endothelial cells.Metabolic brain disease · 2022Article
- Clinical relevance of circulating angiogenic cells in patients with ischemic stroke.BMC cardiovascular disorders · 2022Observational
- Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.Current neuropharmacology · 2022Review
- Unraveling the potential of endothelial progenitor cells as a treatment following ischemic stroke.Frontiers in neurology · 2022Review
- Role of Stromal Cell-Derived Factor-1 in Endothelial Progenitor Cell-Mediated Vascular Repair and Regeneration.Tissue engineering and regenerative medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke continues to be a leading cause of mortality and morbidity in the world. Despite recent advances in the field of stroke medicine, thrombolysis with recombinant tissue plasminogen activator remains as the only pharmacological therapy for stroke patients. However, due to short therapeutic window (4.5 hours of stroke onset) and increased risk of hemorrhage beyond this point, each year globally less than 1% of stroke patients receive this therapy which necessitate the discovery of safe and efficacious therapeutics that can be used beyond the acute phase of stroke. Accumulating evidence indicates that endothelial progenitor cells (EPCs), equipped with an inherent capacity to migrate, proliferate and differentiate, may be one such therapeutics. However, the limited availability of EPCs in peripheral blood and early senescence of few isolated cells in culture conditions adversely affect their application as effective therapeutics. Given that much of the EPC-mediated reparative effects on neurovasculature is realized by a wide range of biologically active substances released by these cells, it is possible that EPC-secretome may serve as an important therapeutic after an ischemic stroke. In light of this assumption, this review paper firstly discusses the main constituents of EPC-secretome that may exert the beneficial effects of EPCs on neurovasculature, and then reviews the currently scant literature that focuses on its therapeutic capacity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.